Swiss Biotech Day: Milan based Genenta Science recently raised €20 million from a government investment fund as it takes its cell therapy into the clinic in renal cell carcinoma
- May 6, 2025
- 1 min read
Co-Founder and CEO Pierluigi Paracchi describes the terms of the convertible bond raise, which gives the investor, ENEA Tech and Biomedical, the opporutnity to convert to equity in three years. He also provides an update on the progress of dosing renal cell carcinoma patients in the clinic, and what we can expect from the trial throughout the rest of the year.
.png){kind=logo}